Seroatlas · Human Serome Atlas

BCAR3

Breast cancer anti-estrogen resistance protein 3

Also known as: AND-34, BCAR3_HUMAN, MIG7, NSP2, SH2D3B

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O75815
Gene
BCAR3
Ensembl
ENSG00000137936
Chromosome
1
Canonical length
825 aa
Protein class
Predicted intracellular proteins
Subcellular location
Plasma membrane,Centrosome,Cytosol

OverviewNCBI Gene

Breast tumors are initially dependent on estrogens for growth and progression and can be inhibited by anti-estrogens such as tamoxifen. However, breast cancers progress to become anti-estrogen resistant. Breast cancer anti-estrogen resistance gene 3 was identified in the search for genes involved in the development of estrogen resistance. The gene encodes a component of intracellular signal transduction that causes estrogen-independent proliferation in human breast cancer cells. The protein contains a putative src homology 2 (SH2) domain, a hall mark of cellular tyrosine kinase signaling molecules, and is partly homologous to the cell division cycle protein CDC48. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012]

Canonical amino-acid sequenceUniProt

825 residues, UniProt reviewed canonical sequence.

>O75815|BCAR3
     1  MAAGKFASLP RNMPVNHQFP LASSMDLLSS RSPLAEHRPD AYQDVSIHGT LPRKKKGPPP
    61  IRSCDDFSHM GTLPHSKSPR QNSPVTQDGI QESPWQDRHG ETFTFRDPHL LDPTVEYVKF
   121  SKERHIMDRT PEKLKKELEE ELLLSSEDLR SHAWYHGRIP RQVSENLVQR DGDFLVRDSL
   181  SSPGNFVLTC QWKNLAQHFK INRTVLRLSE AYSRVQYQFE MESFDSIPGL VRCYVGNRRP
   241  ISQQSGAIIF QPINRTVPLR CLEEHYGTSP GQAREGSLTK GRPDVAKRLS LTMGGVQARE
   301  QNLPRGNLLR NKEKSGSQPA CLDHMQDRRA LSLKAHQSES YLPIGCKLPP QSSGVDTSPC
   361  PNSPVFRTGS EPALSPAVVR RVSSDARAGE ALRGSDSQLC PKPPPKPCKV PFLKVPSSPS
   421  AWLNSEANYC ELNPAFATGC GRGAKLPSCA QGSHTELLTA KQNEAPGPRN SGVNYLILDD
   481  DDRERPWEPA AAQMEKGQWD KGEFVTPLLE TVSSFRPNEF ESKFLPPENK PLETAMLKRA
   541  KELFTNNDPK VIAQHVLSMD CRVARILGVS EEMRRNMGVS SGLELITLPH GHQLRLDIIE
   601  RHNTMAIGIA VDILGCTGTL EDRAATLSKI IQVAVELKDS MGDLYSFSAL MKALEMPQIT
   661  RLEKTWTALR HQYTQTAILY EKQLKPFSKL LHEGRESTCV PPNNVSVPLL MPLVTLMERQ
   721  AVTFEGTDMW EKNDQSCEIM LNHLATARFM AEAADSYRMN AERILAGFQP DEEMNEICKT
   781  EFQMRLLWGS KGAQVNQTER YEKFNQILTA LSRKLEPPPV KQAEL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BCAR3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.47
Highest tissue expression
29 nTPM

Expression across tissuesHPA

Tissue

  • adipose tissue: 29 nTPM
  • skeletal muscle: 23 nTPM
  • salivary gland: 21 nTPM
  • tongue: 20 nTPM
  • breast: 18 nTPM
  • choroid plexus: 17 nTPM

Single-cell type

  • podocytes: 338 nCPM
  • endometrial secretory cells: 277 nCPM
  • bergmann glia: 273 nCPM
  • extravillous trophoblasts: 244 nCPM
  • microglia: 206 nCPM
  • choroid plexus epithelial cells: 204 nCPM

Immune cell

  • basophil: 2 nTPM
  • memory B-cell: 1.8 nTPM
  • naive B-cell: 1.6 nTPM
  • plasmacytoid DC: 0.7 nTPM
  • intermediate monocyte: 0.4 nTPM
  • myeloid DC: 0.3 nTPM

Brain region

  • thalamus: 31 nTPM
  • choroid plexus: 30 nTPM
  • medulla oblongata: 30 nTPM
  • midbrain: 29 nTPM
  • basal ganglia: 29 nTPM
  • cerebellum: 26 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about BCAR3.

Disease | ImmuneIEDB

Conditions an epitope on BCAR3 was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.38
gnomAD pLI
0.58
gnomAD missense Z
0.3
DepMap mean gene effect
-0.11
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of BCAR3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BCAR3 as an antibody target. Whether an autoantibody or antibody against BCAR3 could matter depends on whether native BCAR3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BCAR3 is annotated at the cell surface, where native BCAR3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label BCAR3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/BCAR3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...